Stocks Health care ZVSA

OTC · Health care

ZyVersa Therapeutics, Inc. (ZVSA)

It posted a net loss of $24.5M. At March 31, 2026 it held $302.7K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 13, 2026.

Watch ZVSA in 60 seconds

What ZyVersa Therapeutics, Inc. does

ZyVersa Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ZVSA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What ZyVersa Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. July 16, 2026
   Other event 8-K
2. July 10, 2026
   Executive or director change 8-K
3. May 13, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.22 versus -$0.73.
4. March 31, 2026
   Annual report 10-K · period to December 31, 2025Diluted EPS -$4.18 versus -$8.48.
5. March 5, 2026
   Material agreement 8-K
6. December 3, 2025
   Executive or director change 8-K
7. November 19, 2025
   Quarterly results 8-K
8. November 19, 2025
   Quarterly report 10-Q · period to September 30, 2025Diluted EPS -$2.56 versus -$2.43.
9. November 14, 2025
   Late quarterly report notice NT 10-Q
10. October 15, 2025
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 16, 2025. Insider transactions on SEC

Insider trades

What the people running ZyVersa Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about ZVSA

What does ZyVersa Therapeutics, Inc. do?

ZyVersa Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ZVSA.

Is ZyVersa Therapeutics, Inc. profitable?

No. Over the twelve months to March 31, 2026 it reported a net loss of $24.5M.

When did ZyVersa Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on May 13, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the other event from July 16, 2026.

Similar companies

Compare ZVSA with

Compare ZVSA with any company

Follow ZVSA

Get an email when ZyVersa Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ZVSA: get an email when it files

Where the numbers come from

Financial figures are the values ZyVersa Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.